Thousands of people in England with a type of multiple sclerosis (MS) are set to benefit from a new treatment on the NHS. Patients may have the treatment in cases when MS remains highly active after other therapies, or when other treatments are not suitable. MS is an autoimmune disease which causes immune cells to attack myelin, the insulating layer that protects nerves in the brain and spinal cord. Helen Knight, director of medicines evaluation, said: ‘This recommendation means people living with highly active relapsing-remitting MS now have a meaningful additional treatment option. ‘Natalizumab is a highly effective treatment, and we’re really pleased that people with highly active relapsing MS who haven’t responded to previous disease-modifying therapies (DMTs) will now have the option to take it.
